Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Share-based Compensation (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Share-based Compensation for 6 consecutive years, with $105.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 48.92% year-over-year to $105.0 million, compared with a TTM value of $474.5 million through Dec 2025, down 1.2%, and an annual FY2025 reading of $289.0 million, up 44.78% over the prior year.
  • Share-based Compensation was $105.0 million for Q4 2025 at Roivant Sciences, up from $81.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $487.8 million in Q4 2021 and bottomed at $19.3 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $138.6 million, with a median of $81.8 million recorded in 2025.
  • Peak annual rise in Share-based Compensation hit 277.78% in 2022, while the deepest fall reached 84.4% in 2022.
  • Year by year, Share-based Compensation stood at $487.8 million in 2021, then tumbled by 60.54% to $192.5 million in 2022, then dropped by 20.57% to $152.9 million in 2023, then soared by 34.43% to $205.5 million in 2024, then tumbled by 48.92% to $105.0 million in 2025.
  • Business Quant data shows Share-based Compensation for ROIV at $105.0 million in Q4 2025, $81.8 million in Q3 2025, and $82.2 million in Q2 2025.